Log-in
E-Mail
Passwort
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Anmelden
Anmelden
Neukunde
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

MarketScreener Homepage  >  Aktien  >  Swiss Exchange  >  Idorsia Ltd    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Report  
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFundamentaldatenAnalystenschätzungenRevisionenDerivate 
News-ÜbersichtNewsOffizielle PublikationenBranchennachrichtenAnalysten Empfehlungen zu

GNW: Janssen reports new head-to-head Phase 3 study data show ponesimod

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11.09.2019 | 16:33

superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis

.      OPTIMUM Phase 3 study data presented for the first time during oral presentation at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis 

.      Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have a Revenue Sharing Agreement in respect to ponesimod

Allschwil, Switzerland - September 11, 2019 Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the results from the Phase 3 OPTIMUM study for ponesimod, an investigational selective S1P1 receptor modulator, showing superior efficacy on the primary endpoint and most secondary endpoints compared to Aubagio(R) (teriflunomide)* 14 mg in adults with relapsing multiple sclerosis (MS).

For further details please read the full announcement available here: https://www.janssen.com/new-head-head-phase-3-study-data-show-ponesimod-superiority-versus-aubagio-teriflunomide-14-mg

About the Revenue Sharing Agreement Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have entered into the Revenue Sharing Agreement in respect to ponesimod. Under the terms of the Revenue Sharing Agreement, Idorsia Pharmaceuticals Ltd is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion Pharmaceuticals Ltd.

* Aubagio(R) is a registered trademark of Sanofi Société Anonyme France.

Notes to the editor

About Idorsia Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core.

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact Andrew C. Weiss Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 (0) 58 844 10 10 www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Anhang

* Medienmitteilung PDF

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Aktuelle News zu IDORSIA LTD
11.09.Idorsia-Partner Janssen stellt Studienergebnisse zu Ponesimod in Stockholm vo..
AW
09.09.Aktien Schweiz: SMI konsolidiert nahe Rekordhoch - Defensive bremsen
AW
04.09.Aktien Schweiz Vorbörse: Fester gesehen - Rückenwind von der Europa-Politik
AW
29.08.Idorsia-Aktien vor wichtigen Daten stark gefragt
AW
26.08.Idorsia will laut CEO bereits 2021 in die schwarzen Zahlen kommen
AW
26.08.BÖRSE ZÜRICH : Morning Briefing - Markt Schweiz
AW
23.08.Idorsia gibt klinische Daten für Aprocitentan und Selatogrel in Paris bekannt
AW
26.07.Aktien Schweiz: Nestlé führen festeren SMI an
AW
26.07.Aktien Schweiz Eröffnung: Kursplus dank defensiven Schwergewichten
AW
26.07.BÖRSE ZÜRICH : Morning Briefing - Markt Schweiz
AW
Mehr News
News auf Englisch zu IDORSIA LTD
11.09.Janssen reports new head-to-head Phase 3 study data show ponesimod superiorit..
GL
03.09.Phase 2 data of selatogrel, Idorsia's highly-selective P2Y12 receptor antagon..
GL
31.08.Phase 2 data of aprocitentan, Idorsia's dual endothelin receptor antagonist, ..
GL
23.08.Clinical data on Idorsia's pipeline compounds will be presented at the Europe..
GL
23.07.Idorsia announces financial results for the first half of 2019
GL
16.07.Invitation to Idorsia's half year financial results 2019 webcast and conferen..
GL
14.06.IDORSIA : Efficacy and safety data with Idorsia's dual orexin receptor antagonis..
AQ
13.06.Efficacy and safety data with Idorsia's dual orexin receptor antagonist prese..
GL
07.06.ACTELION : A Platform Approach Simplifies Clinical Workflow For Idorsia Pharma
AQ
03.05.IDORSIA : holds its second Annual General Meeting of Shareholders - All Board pr..
AQ
Mehr News auf Englisch
Finanzkennziffern (CHF)
Umsatz 2019 28,8 Mio
EBIT 2019 -534 Mio
Nettoergebnis 2019 -531 Mio
Liquide Mittel 2019 14,1 Mio
Div. Rendite 2019 -
KGV 2019 -6,53x
KGV 2020 -9,29x
Marktkap. / Umsatz2019 118x
Marktkap. / Umsatz2020 40,7x
Marktkap. 3 425 Mio
Chart IDORSIA LTD
Dauer : Zeitraum :
Idorsia Ltd : Chartanalyse Idorsia Ltd | MarketScreener
Vollbild-Chart
Trends aus der Chartanalyse IDORSIA LTD
KurzfristigMittelfristigLangfristig
TrendsAnsteigendAnsteigendAnsteigend
Ergebnisentwicklung
Analystenschätzung
Verkauf
Kaufen
Durchschnittl. Empfehlung HALTEN
Anzahl Analysten 5
Mittleres Kursziel 21,20  CHF
Letzter Schlusskurs 26,10  CHF
Abstand / Höchstes Kursziel 14,9%
Abstand / Durchschnittliches Kursziel -18,8%
Abstand / Niedrigsten Ziel -38,7%
Revisionen zum Gewinn/Aktie
Unternehmensführung
NameTitel
Chief Executive Officer & Director
Chairman
Chief Financial Officer & Executive Vice President
Head-Global Clinical Development & Executive VP
Chief Scientific Officer & Executive VP
Branche und Wettbewerber
01.01.Marktkap. (M$)
IDORSIA LTD60.91%3 448
GILEAD SCIENCES6.19%84 118
VERTEX PHARMACEUTICALS7.49%45 783
REGENERON PHARMACEUTICALS-20.78%32 375
GENMAB31.33%13 425
NEUROCRINE BIOSCIENCES, INC.41.20%9 234